公开(公告)号：US20210369761A1

公开(公告)日：2021-12-02

申请号：US17391125

申请日：2021-08-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran HORNSTEIN ,  Irit REICHENSTEIN ,  Alon CHEN

IPC: A61K31/7105 ,  C12N15/113 ,  A61K45/06 ,  A61P25/00

Abstract: A method of treating a subject having MND is provided. The method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of miR-218, miR-218*, precursor thereof and a polynucleotide sequence encoding miR-218 or miR-218* or precursor thereof, thereby treating the MND in the subject. A method of treating a subject having MND, the method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating an activity or expression of a gene product selected from the group consisting of KCND2, KCNH1, GABRB2, SLC6A1, SLC6A11, KCNA1, CACNB4, GRIA2, GRIK2, GABRG1 and GRIK3, is also provided.

公开(公告)号：US20200246372A1

公开(公告)日：2020-08-06

申请号：US16854978

申请日：2020-04-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran HORNSTEIN ,  Irit REICHENSTEIN ,  Alon CHEN

IPC: A61K31/7105 ,  A61P25/00 ,  A61K45/06 ,  C12N15/113

Abstract: A method of treating a subject having MND is provided. The method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of miR-218, miR-218*, precursor thereof and a polynucleotide sequence encoding miR-218 or miR-218* or precursor thereof, thereby treating the MND in the subject. A method of treating a subject having MND, the method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating an activity or expression of a gene product selected from the group consisting of KCND2, KCNH1, GABRB2, SLC6A1, SLC6A11, KCNA1, CACNB4, GRIA2, GRIK2, GABRG1 and GRIK3, is also provided.

公开(公告)号：US20180064748A1

公开(公告)日：2018-03-08

申请号：US15561990

申请日：2016-03-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran HORNSTEIN ,  Irit REICHENSTEIN ,  Alon CHEN

IPC: A61K31/7105 ,  C12N15/113

CPC classification number: A61K31/7105 ,  A61K45/06 ,  A61P25/00 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/141

Abstract: A method of treating a subject having MND is provided. The method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of miR-218, miR-218*, precursor thereof and a polynucleotide sequence encoding miR-218 or miR-218* or precursor thereof, thereby treating the MND in the subject. A method of treating a subject having MND, the method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating an activity or expression of a gene product selected from the group consisting of KCND2, KCNH1, GABRB2, SLC6A1, SLC6A11, KCNA1, CACNB4, GRIA2, GRIK2, GABRG1 and GRIK3, is also provided.